Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Recalls, Market Withdrawals, & Safety Alerts

Recalls, Market Withdrawals, & Safety Alerts

                        Recall Resources


                        Enforcement Reports
          Industry Guidance For Recalls
          Major Product Recalls
          Archive for Recalls, Market Withdrawals & Safety Alerts Home
          Safety
          Recalls, Market Withdrawals, & Safety Alerts
          Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue ExpandersRecalls, Market Withdrawals, & Safety Alerts COMPANY ANNOUNCEMENT
    
  
  
  Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders

  
    
        When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.
      Read Announcement View Product Photos
  
  
  Share
    Post
    Linkedin

    Email
    PrintSummary

  Company Announcement Date:
             July 24, 2019

                          FDA Publish Date: 
               July 25, 2019
                                    Product Type: 
              Medical Devices                          
            
            
            
            
            
            
            
             
            
              
              General & Plastic Surgery
                          Reason for Announcement:
              Recall Reason Description
              Due to uncommon incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)

            Company Name: 
              Allergan plc

            Brand Name:
              Brand Name(s)
          BIOCELL®

            Product Description:
              Product Description
          BIOCELL® textured breast implants and tissue expanders   
Company Announcement



*-- Global Action Follows Notification of Updated Safety Information from the U.S. Food and Drug Administration (FDA) --*

*-- FDA Does Not Recommend Removal or Replacement of Textured Breast Implants in Asymptomatic Patients --*

*--Smooth and MICROCELL®Breast Implants and Tissue Expanders Not Impacted --*



DUBLIN, July 24, 2019/PRNewswire/ --Allergan plc (NYSE: AGN) today announced a voluntary worldwide recall of BIOCELL®textured breast implants and tissue expanders. Allergan is taking this action as a precaution following notification of recently updated global safety information concerning the uncommon incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) provided by the U.S. Food and Drug Administration (FDA).

BIOCELL®saline-filled and silicone-filled textured breast implants and tissue expanders will no longer be distributed or sold in any market where they are currently available. Effective immediately, healthcare providers should no longer implant new BIOCELL® textured breast implants and tissue expanders and unused products should be returned to Allergan. Allergan will provide additional information to customers about how to return unused products.

Patient safety is a priority for Allergan. Patients are advised to speak with their plastic surgeon about the risks and benefits of their implant type should they have any concerns.

Importantly, the FDA and other health authorities have not recommended removal or replacement of textured breast implants or tissue expanders in asymptomatic patients.

This global recall does not affect Allergan's NATRELLE® smooth or MICROCELL® breast implants and tissue expanders.

The recalled products include:

Natrelle Saline breast implant styles 168, 363, 468Natrelle and McGhan 410 breast implant styles LL, LM, LF, LX, ML, MM, MF, MX, FL, FM, FF, FXNatrelle and McGhan 410 *Soft Touch* breast implant styles LL, LM, LF, LX, ML, MM, MF, MX, FL, FM, FF, FXNatrelle 510 Dual-Gel styles LX, MX, FXNatrelle INSPIRA breast implants, styles TRL, TRLP, TRM, TRF, TRX, TSL, TSLP, TSM, TSF, TSX, TCL, TCLP, TCM, TCF, TCXNatrelle and McGhan Round Gel Implants, styles 110, 110 Soft Touch, 120, 120 Soft TouchNatrelle Komuro breast implants styles KML, KMM, KLL, and KLMNatrelle Ritz Princess breast implant styles RML, RMM, RFL, RFMNatrelle 150 Full Height and Short Height double lumen implantsNatrelle 133 tissue expanders with and without suture tabs: styles 133FV, 133MV, 133LV, 133MX, 133SX, 133SV, T-133FV,
			T-133MV, T-133LV, T-133MX, T-133SX, T-133SV, 133FV-T, 133MV-T, 133LV-T, 133MX-T, 133SX-T, 133SV-TNatrelle 133 Plus tissue expander styles 133P-FV, 133P-MV, 133P-LV, 133P-MX, 133P-SX,
			133P-SV, T-133P-FV, T-133P-MV, T-133P-LV, T-133P-MX, T-133P-SX, T-133P-SV, 133P-FV-T, 133P-MV-T, 133P-LV-T, 133P-MX-T, 133P-SX-T, 133P-SV-T

U.S. healthcare providers with questions regarding this announcement can contact Medical Information at 1-800-678-1605 option #2 or IR-Medcom@allergan.com. For all other countries, please use the contact details at the following link on Allergan's website: Allergan Global Medical Information Contacts.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online
	Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:
Allergan:
Investors:
Manisha Narasimhan, PhD
(862) 261-7162
Christine Chiou
(862) 261-7396
Media:
Fran DeSena
(862) 261 8820
Mark Marmur
+44 7725 758677
Lisa Brown
(862) 261-7320

View original content to download multimedia: http://www.prnewswire.com/news

Link to FDA Announcement

Additional Information





Company Contact Information
  
  
    Consumers:       

                 Medical Information
        
                 1-800-678-1605 option #2
        
                 IR-Medcom@allergan.com
    Media:
      
              Fran DeSena, Mark Marmur, Lisa Brown
      
              (862) 261 8820, +44 7725 758677, (862) 261-7320



  Product Photos

            Allergen plc logo

                                                                                  Content current as of:
      07/25/2019
               
             
Regulated Product(s)
		 Medical Devices
			  			     			  						              
			
			
			
			
			
			
			  
			  General & Plastic Surgery   
        
        Follow FDA
            Follow@US_FDAon X
              FollowFDAon Facebook
              Follow@FDArecallson X
              Recent Recalled Product Photos on FDA's Flickr PhotostreamMore Recalls, Market 
    Withdrawals, & 
    Safety Alerts

        Recalls, Market Withdrawals, & Safety Alerts

          
                        Recall Resources


                        Enforcement Reports
          Industry Guidance For Recalls
          Major Product Recalls
          Archive for Recalls, Market Withdrawals & Safety Alerts
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop